Chemotherapy of neuroendocrine tumours;Chimiothérapie des tumeurs neuro-endocrines

Revue du Praticien

Volumn 52, Issue 3, 2002, Pages 285-289

  Droz, Jean Pierre ^a   Flechon, Aude ^a   Lombard Bohas, Catherine ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; STREPTOZOCIN;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; ENTEROCHROMAFFIN CELL; INSULINOMA; NEUROENDOCRINE TUMOR; SURVIVAL TIME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; EMBOLIZATION, THERAPEUTIC; ETOPOSIDE; HUMANS; NEUROENDOCRINE TUMORS; PROGNOSIS; STREPTOZOCIN; SURVIVAL ANALYSIS;

EID: 0036470706     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Carcinoid tumors and the carcinoid syndrome
2. Pancreatic endocrine tumors
3. Chemotherapy for malignant neuroendocrine tumours
4. Pancreatic islet cell carcinoma: II. results of therapy with streptozotocin in 52 patients
5. Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest oncology group study
6. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma
7. The management of patients with advanced carcinoid tumors and islet cell carcinoma
8. Treatment of major therapeutic activity in the anaplastic variants of these neoplasms
9. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma
10. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors
11. Metastatic carcinod and islet cell tumours of the pancreas: A phase trial of the efficacy of combination chemotherapy with 5-fluorouracile
12. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest oncology group study
13. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinod tumor
14. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity
15. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
16. Pancreatic islet cell carcinoma: I. Clinical features of 52 patients